| ID | 69099 |
| フルテキストURL | |
| 著者 |
Morita, Mizuki
Department of Biomedical Informatics, Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University
Honjoh, Mina
Faculty of Health Sciences, Okayama University Medical School
Yamane, Takahiro
Department of Biomedical Informatics, Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University
|
| 抄録 | This study examined clinical trial trends to guide digital biomarker (dBM) guideline development. Analysis of 2005–2023 data was conducted to assess the frequency and types of dBM used as endpoints (dEP) in these trials and the associated target diseases. Clinical trials using dEP increased from 0–7 per year (2005–2019) to 15–20 annually from 2020. Endocrine and metabolic conditions were the most common targets, showing a distinct disease distribution compared to overall trials. Most measurements used actigraphy devices or blood glucose sensors, with glucose sensors focusing on metabolic conditions while actigraphy covered broader applications. Additionally, 42.4% of trials used dEP as primary endpoints. While dEP use is growing, it remains limited in disease scope and device variety. Expanding both would enhance their utility in clinical research.
|
| キーワード | Clinical endpoint,
clinical outcomes
wearable devices
|
| 備考 | Proceedings of the 20th World Congress on Medical and Health Informatics
Studies in Health Technology and Informatics, Volume 329
|
| 発行日 | 2025-08-07
|
| 出版物タイトル |
MEDINFO 2025 — Healthcare Smart × Medicine Deep
|
| 出版者 | IOS Press
|
| 開始ページ | 391
|
| 終了ページ | 395
|
| ISSN | 0926-9630
|
| 資料タイプ |
会議発表論文
|
| 言語 |
英語
|
| OAI-PMH Set |
岡山大学
|
| 著作権者 | © 2025 The Authors.
|
| 論文のバージョン | publisher
|
| DOI | |
| 関連URL | isVersionOf https://doi.org/10.3233/shti250868
|
| ライセンス | https://creativecommons.org/licenses/by-nc/4.0/
|
